Document is current

Article History

Received: 11 August 2025

Accepted: 12 September 2025

First Online: 26 September 2025

Declarations

:

: Felix Witte: declares no conflicts of interest. Elke Weisshaar: has received speaker honoraria/consulting fees from Sanofi, Menlo, TREVI and Galderma. Martin Metz: is an investigator for Almirall, Celldex, Escient, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi, Teva and has received speaker honoraria/travel fees from Almirall, AbbVie, Celldex, Escient, Incyte, Galderma, Pfizer, Regeneron, Sanofi, Teva and Vifor. Steffen Koschmieder: is an investigator for Pfizer, Incyte / Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, MPN Hub, Sierra Oncology, GlaxoSmith Kline, AbbVie, PharmaEssentia and has received speaker honoraria/travel fees from Alexion, Novartis, BMS, Celgene, Incyte / Ariad, AOP Pharma, CTI, Pfizer, Sanofi, Janssen, Geron, Imago Biosciences, GSK, PharmaEssentia, Sierra Oncology, AbbVie, iOMEDICO, Shire, Roche, AOP Pharma, Karthos, Abbvie, Baxalta, Sierra Oncology, Imago Biosciences. Susanne Isfort: is an investigator for Pfizer, Incyte, GSK, Silence Therapeutics, Novartis and has received speaker honoraria/travel fees from AOP Orphan, Alexion, Janssen, Novartis, Pfizer, Mundipharma, Roche, Hexal, AbbVie, BMS, Incyte, GSK, Silence Therapeutics. Andreas E. Kremer: is an investigator and/or speaker and/or advisor for Abbvie, Advanz, Alentis, AlphaSigma, Astellas, AstraZeneca, Attovia Therapeutics, Avior, Bayer, BMS, Böhringer Ingelheim, CymaBay, Dr. Falk, Gilead, GSK, Guidepoint, Intercept, Ipsen, Mirum, MSD, Novo Nordisk, Rectify Pharma, Roche, Takeda, PBC Foundation, Swiss Association for the Study of the Liver (SASL), Swiss Hepa and has received speaker honoraria/travel fees from Abbvie, Advanz, Alentis, AlphaSigma, Astellas, AOP Orphan, AstraZeneca, Attovia Therapeutics, Avior, Bayer, BMS, Böhringer Ingelheim, CymaBay, Falk Foundation, Gilead, GSK, Guidepoint, Intercept, Ipsen, Johnson&Johnson, Medscape, Mirum, MSD, Newbridge, Novartis, Novo Nordisk, Rectify Pharma, Roche, Takeda, Vertex Viofor. Martin Griesshammer: has received speaker honoraria/travel fees from AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK. Svenja Royeck: was advisor, speaker or investigator for Incyte Inc., Eli Lilly, LEO Pharma and Sanofi/Regeneron. Sonja Ständer: was speaker and/or consultant and/or investigator and/or has received research funding from Almirall S. A., Amgen Inc., Amgen Europe GmbH, Celldex Therapeutics Inc., Clexio Biosiences Ltd., Focus-Insight Healthtech Group Co. Ltd., Galderma Laboratorium GmbH, Galderma R&D LLC., Galderma S.A., GSK R&D Ltd., Incyte Corporation, Klirna Biotech Inc., Leo Pharma, Lilly Deutschland GmbH, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R&D, Sanofi Genzyme Corporation, TouchIME, Vifor Pharma Deutschland GmbH P. G. Unna Academy. Claudia Zeidler: is an investigator for Amgen, Novartis, Janssen, Pfizer, UCB, Lilly, Abbvie, Boehringer Ingelheim, Sanofi, Regeneron, Leo, Galderma and has received speaker honoraria/travel fees from Dermasence, Beiersdorf, Leo, Sanofi, Novartis, Unna Akademie, Allmiral and AbbVie.

: This study was reviewed and approved by Ärztekammer Westfalen Lippe and the Medical Faculty of the University of Münster (2014-162-f-S) and from each participating center (hematology centers at the universities of Erlangen, Aachen, and Minden; dermatology centers at the universities of Münster, Berlin, and Heidelberg) and was registered in the German Clinical Trials Registry (DRKS 00006075). The patients in this manuscript have given written informed consent to the participation in this study. This study was performed according to the principles laid down in the Declaration of Helsinki and following the Guidelines of Good Clinical Practice.